info@mail.ucallm.com
From Molecular Classification to Precision Pulmonary Oncology — Empowering Comprehensive Lung Cancer Profiling with Validated Antibody Solutions
Lung cancer remains the leading cause of cancer-related mortality worldwide, driven by extensive molecular heterogeneity, diverse histological subtypes, complex tumor evolution, and variable therapeutic responses. Advances in precision oncology have transformed lung cancer management through targeted therapies and immune checkpoint inhibitors; however, accurate molecular characterization and biomarker-driven patient stratification remain critical challenges.
Key molecular regulators involved in lineage specification, oncogenic signaling, epithelial–mesenchymal transition (EMT), immune regulation, DNA damage response, angiogenesis, and tumor metabolism provide essential insights into lung cancer initiation, progression, and therapeutic resistance.
We support advanced lung cancer biomarker research by enabling comprehensive investigation of tumor heterogeneity, molecular evolution, immune regulation, metastasis, cancer metabolism, and spatial tumor biology. Validated biomarker solutions empower researchers to characterize molecular subtypes, investigate clonal evolution and therapy resistance, dissect EMT and cancer stemness, and uncover immune checkpoint mechanisms underlying tumor progression and therapeutic response. Combined with single-cell analysis, spatial profiling, multiplex imaging, and AI-assisted digital pathology, lung cancer biomarker profiling enables high-resolution characterization of tumor heterogeneity, tumor–immune interactions, metabolic adaptation, and clinically relevant molecular phenotypes. These integrated approaches accelerate discoveries in precision pulmonary oncology, biomarker-guided therapeutic development, immuno-oncology, metastasis research, and next-generation precision medicine.
Lung Cancer Biomarker Antibody Portfolio
——Comprehensive Solutions for Tumor Classification, Molecular Profiling, and Precision Oncology Research
Accurate lung cancer characterization requires integrated analysis of lineage markers, oncogenic drivers, immune biomarkers, metastatic signatures, and pathway alterations. Our antibody portfolio covers major lung cancer biomarker categories to support standardized research workflows.
Biomarker Category | Representative Markers | Research Applications | Biological Significance |
Lung Cancer Lineage & Subtype Markers | TTF-1, Napsin A, p40, CK5/6, CK7, Synaptophysin, Chromogranin A,CD56, INSM1 | Histological classification and tumor origin identification | Define lung adenocarcinoma, squamous carcinoma, and neuroendocrine tumor identity |
Targeted Therapy Biomarkers | EGFR, ALK, ROS1, MET, RET, NTRK, KRAS, BRAF | Molecular alteration studies and therapeutic stratification | Identify actionable oncogenic drivers |
Immune Microenvironment & Checkpoint Markers | PD-L1, PD-1, CD8, FOXP3, CD68, CD163 , Granzyme B | Immunotherapy response research | Characterize tumor immune landscape |
Prognostic & Metastasis Markers | E-Cadherin, Vimentin, N-Cadherin, MMP9, CD44 | EMT and metastatic mechanism studies | Reflect tumor invasion, recurrence, and treatment resistance |
Tumor Suppressor & DNA Repair Markers | TP53, RB1, BRCA1, ATM, PTEN | Genomic instability research | Reveal mechanisms of tumor evolution |
Cell Proliferation Markers | Ki-67, Cyclin D1, PCNA | Tumor growth evaluation | Assess proliferative activity |
Angiogenesis & Hypoxia Markers | VEGFA, VEGFR2, HIF-1α, CD31 | Tumor vascular biology studies | Investigate angiogenic remodeling |
Cancer Stem Cell Markers | ALDH1A1, SOX2, OCT4, CD133 | Tumor initiation and resistance studies | Explore stemness-associated mechanisms |
Cancer Metabolism Markers | GLUT1, HK2, LDHA, MCT4 | Metabolic reprogramming studies | Characterize metabolic adaptation |
For Research Use Only. Not for use in diagnostic procedures
Key Lung Cancer Biomarker Targets
——Molecular Functions and Research Applications
Marker | Biological Function | Research Value | Associated Lung Cancer Types |
TTF-1 | Nuclear transcription factor regulating lung epithelial differentiation | Lung adenocarcinoma identification and lineage confirmation | Lung adenocarcinoma |
Napsin A | Aspartic protease expressed in pneumocytes | Histological classification | Lung adenocarcinoma |
p40 | Squamous differentiation marker | Distinguish squamous carcinoma subtype | Lung squamous cell carcinoma |
EGFR | Receptor tyrosine kinase regulating proliferation signaling | Targeted therapy biomarker studies | NSCLC |
ALK | Fusion-driven oncogenic kinase | ALK-targeted therapy research | NSCLC |
ROS1 | Receptor tyrosine kinase oncogenic driver | Molecular profiling and therapy selection | NSCLC |
KRAS | Small GTPase regulating MAPK signaling | Mutation-driven tumor biology studies | Lung adenocarcinoma |
TP53 | Tumor suppressor controlling genomic stability | Molecular subtype and progression studies | NSCLC/SCLC |
PD-L1 | Immune checkpoint ligand | Immunotherapy biomarker evaluation | NSCLC |
CD8 | Cytotoxic T-cell marker | Tumor immune infiltration analysis | NSCLC |
CD44 | Adhesion receptor associated with cancer stemness | Metastasis and resistance studies | Advanced lung cancer |
Vimentin | Mesenchymal marker associated with EMT | Invasion and metastatic research | NSCLC |
E-Cadherin | Epithelial adhesion protein | EMT transition studies | Lung carcinoma |
VEGFA | Angiogenic growth factor | Anti-angiogenic therapy studies | NSCLC |
Ki-67 | Nuclear proliferation marker | Tumor growth assessment | Lung cancer |
SOX2 | Stem cell transcription factor | Tumor initiation research | Squamous carcinoma |
BRAF | Kinase; V600E mutation leads to constitutive MAPK signaling. | Mutation-specific (V600E) detection for targeted therapy. | NSCLC (adenocarcinoma) |
Synaptophysin | Neuroendocrine secretory vesicle protein. | Defining neuroendocrine differentiation in SCLC and lung NETs. | SCLC, lung NET |
Chromogranin A | Neuroendocrine granule protein | Highly specific neuroendocrine marker. | SCLC, lung NET |
CD56 (NCAM1) | Neural cell adhesion molecule expressed on neuroendocrine cells. | Sensitive marker for SCLC (often used in combination). | SCLC |
Featured Lung Cancer Research Panels
——Integrated Biomarker Solutions for Comprehensive Tumor Characterization
Non-Small Cell Lung Cancer (NSCLC) Classification Panel——Defining Lung Cancer Lineage and Molecular Identity
Key Markers
TTF-1 | Napsin A | p40 | CK5/6 | CK7 | Ki-67 |
Targeted Therapy Biomarker Panel——Characterizing Actionable Molecular Alterations
Key Markers
EGFR | ALK | ROS1 | MET | RET | KRAS | BRAF |
Immune Oncology & Tumor Microenvironment Panel——Investigating Immunotherapy Response Mechanisms
Key Markers
PD-L1 | PD-1 | CD8 | CD68 | FOXP3 | Granzyme B |
EMT & Metastasis Research Panel——Understanding Tumor Invasion and Therapy Resistance
Key Markers
E-Cadherin | N-Cadherin | Vimentin | CD44 | MMP9 | L1CAM |
Small Cell Lung Cancer (SCLC) Characterization Panel——Defining Neuroendocrine Tumor Biology
Synaptophysin | Chromogranin A | CD56 | INSM1 | SOX2 | Ki-67 |
Lung Cancer Biomarker Research
——From Molecular Profiling to Translational Discovery
Research Stage | Representative Markers | Scientific Objective |
Tumor Classification | TTF-1, Napsin A, p40, Synaptophysin | Define lung cancer histological subtype |
Molecular Profiling | EGFR, ALK, ROS1, KRAS, MET | Identify actionable genomic alterations |
Prognostic Evaluation | Ki-67, TP53, CD44, Vimentin | Evaluate tumor aggressiveness |
EMT & Metastasis Research | E-Cadherin, Vimentin, MMP9 | Investigate invasion mechanisms |
Immune Profiling | PD-L1, CD8, FOXP3, CD68 | Characterize immune microenvironment |
Angiogenesis Research | VEGFA, VEGFR2, CD31 | Study tumor vascular remodeling |
Therapeutic Biomarker Discovery | EGFR, PD-L1, MET, ALK | Evaluate targeted treatment strategies |
The Lung Cancer Biomarker Research Workflow integrates histological classification, molecular profiling, immune characterization, and therapeutic biomarker discovery to support precision oncology research. By evaluating key markers including TTF-1, Napsin A, p40, EGFR, ALK, ROS1, KRAS, PD-L1, and EMT-associated proteins, researchers can define tumor subtype, identify actionable genomic alterations, assess disease progression, and explore mechanisms of invasion and metastasis. This comprehensive workflow enables investigation of the tumor microenvironment, angiogenesis, and treatment response pathways, providing valuable insights for biomarker validation and targeted therapy development.
Why Researchers Choose Our Lung Cancer Biomarker Solutions?
Validated Targets. Comprehensive Panels. Reliable Translational Research.
Our antibody portfolio supports the complete lung cancer research workflow—from tumor classification and molecular profiling to precision medicine and therapeutic development.
Research Challenge | Our Solution |
How can I classify lung cancer subtypes? | Comprehensive lineage marker panels including TTF-1, Napsin A, p40, and neuroendocrine markers |
How can I identify therapeutic targets? | Validated antibodies targeting EGFR, ALK, ROS1, MET, KRAS, and related pathways |
How can I study immunotherapy response? | Immune profiling solutions including PD-L1, CD8, CD68, and FOXP3 |
How can I investigate metastasis and resistance? | EMT and cancer stemness biomarker panels |
How can I improve experimental reproducibility? | Highly validated antibodies optimized for IHC, WB, IF, flow cytometry, and multiplex applications |
Key References
Herbst R.S., Morgensztern D., Boshoff C. (2021). The biology and management of non-small cell lung cancer. Nature. 596:505–513.
Thai A.A., Solomon B.J., Sequist L.V., Gainor J.F., Heist R.S. (2021). Lung cancer. The Lancet. 398:535–554.
Skoulidis F., Li B.T., Dy G.K., et al. (2021). Sotorasib for previously treated KRAS G12C-mutated non–small-cell lung cancer. New England Journal of Medicine. 384:2371–2381.
Remon J., Hendriks L.E.L., Cardona A.F., Besse B. (2022). Current challenges and future prospects of immunotherapy in non-small cell lung cancer. The Lancet Oncology. 23:e379–e391.